郝清云

【摘要】 目的 觀察替格瑞洛联合美托洛尔治疗急性冠状动脉（冠脉）综合征的临床疗效和护理效果。方法 88例急性冠脉综合征患者， 随机将其分为对照组和观察组， 每组44例。对照组患者行替格瑞洛治疗， 观察组患者在对照组的基础上增加美托洛尔治疗。观察并对比两组治疗前后C反应蛋白（CRP）、肌酸激酶-同工酶（CK-MB）、肌钙蛋白T（cTnT）、胸痛总积分水平及心律失常的发生情况， 观察并对比两组患者治疗效果。结果 观察组患者的临床治疗总有效率为95.45%， 高于对照组的81.82%， 差异具有统计学意义（χ2=4.0615， P=0.0438<0.05）。治疗前， 两组患者CRP水平、CK-MB、cTnT、胸痛总积分及心律失常发生率比较， 差异无统计学意义（P>0.05）;治疗后， 两组患者CRP水平、CK-MB水平、cTnT水平及胸痛总积分、心律失常发生率均低于治疗前， 且观察组低于对照组， 差异具有统计学意义（P<0.05）。结论 对急性冠脉综合征患者应用替格瑞洛联合美托洛尔治疗， 相较于单一替格瑞洛治疗疗效更为显著， 可有效抑制患者心肌收缩， 降低猝死率， 值得临床推广。

【关键词】 替格瑞洛;美托洛尔;急性冠状动脉综合征;临床疗效

DOI：10.14163/j.cnki.11-5547/r.2019.17.049

Observation on clinical efficacy of ticagrelor combined with metoprolol in the treatment of acute coronary syndrome   HAO Qing-yun. Shandong Tengzhou Workers Hospital， Tengzhou 277500， China

【Abstract】 Objective   To observe the clinical efficacy and nursing effect of ticagrelor combined with metoprolol in the treatment of acute coronary syndrome. Methods   A total of 88 patients with acute coronary syndrome were randomly divided into control group and observation group， with 44 cases in each group. The control group was treated with ticagrelor， and the observation group was treated with metoprolol on the basis of the control group. Observation and comparison were made on C-reactive protein （CRP）， creatine kinase-MB （CK-MB）， troponin T （cTnT）， total score of chest pain and occurrence of arrhythmia before and after treatment and treatment effect between the two groups. Results   The observation group had higher total effective rate of clinical treatment as 95.45% than 81.82% in the control group， and the difference was statistically significant （χ2=4.0615， P=0.0438<0.05）. Before treatment， both groups had no statistically significant difference in CRP， CK-MB， cTnT， total score of chest pain and incidence of arrhythmia （P>0.05）. After treatment， both groups had lower CRP， CK-MB， cTnT， total score of chest pain and incidence of arrhythmia than those before treatment， and the observation group was lower than the control group. Their difference was statistically significant （P<0.05）. Conclusion   Ticagrelor combined with metoprolol is more effective than single ticagrelor in the treatment of acute coronary syndrome， and it can effectively inhibit myocardial contraction and reduce sudden death rate. It is worthy of clinical promotion.

【Key words】 Ticagrelor; Metoprolol; Acute coronary syndrome; Clinical efficacy